Energy
PrivateThe turnaround is real; the re-rating is not yet earned — a genuinely fixed balance sheet and a 71%-profitable order book are being priced at ~14x forward sales on a green-hydrogen demand ramp the wider industry keeps cancelling. Fade the Rheinmetall/GB-Energy euphoria unless the MW-reservation pipeline converts to firm orders through FY2027.
Research
The verdict
The turnaround is real; the re-rating is not yet earned — a genuinely fixed balance sheet and a 71%-profitable order book are being priced at ~14x forward sales on a green-hydrogen demand ramp the wider industry keeps cancelling. Fade the Rheinmetall/GB-Energy euphoria unless the MW-reservation pipeline converts to firm orders through FY2027.
The model. ITM designs and manufactures PEM electrolyser stacks and plants. Renewable electricity + water in, green hydrogen out. Revenue is overwhelmingly equipment sales — H1 FY2026 revenue of £18.0m split £15.5m equipment / £2.5m engineering, spares and maintenance. It is a lumpy, project-driven, contract-manufacturing P&L, not a recurring-revenue business — today.
Product ladder (2026). Built on the current TRIDENT PEM stack (~670 kW/stack):
Customers. Blue-chip but concentrated and FID-dependent: Shell (REFHYNE II, Rhineland — 100 MW Trident reservation), RWE (150 MW), Yara (24 MW Herøya green-ammonia plant, live), Uniper (Humber H2ub, 6× POSEIDON = 120 MW), Octopus Energy and MorGen Energy (20 MW, Wales) in the UK, plus Norway's Agder Hydrogen Hub (4× NEPTUNE V). customers.csv is empty — all ``.
Contract structure — the crucial nuance. The firm order backlog is £152m (H1 FY2026), of which 71% is now profitable and 29% legacy loss-making, to unwind over ~18 months. The eye-catching 710 MW "Stablegrid", 150 MW RWE and 100 MW REFHYNE II figures are capacity-reservation agreements, not firm backlog — options contingent on the customer's final investment decision (FID). The gap between the MW headline pipeline and the modest £-backlog is the single most important thing to hold in mind for every later lens.
History. Founded June 2000 in Saffron Walden, Essex (Highgate/Lloyd/Wreford), originally a fuel-cell company; AIM IPO 2004 raising £10m. HQ now Sheffield (Bessemer Park gigafactory + two further Sheffield sites) plus an office in Hesse, Germany.
Upstream inputs → ITM → end customer, named where sourced (supply-chain.md missing — all ``):
Chokepoints: (1) iridium — structural, industry-wide, and the reason CHRONOS's −40% iridium claim matters; (2) the Linde relationship — Linde is simultaneously ~16% shareholder, JV partner, EPC channel and a customer, which concentrates both dependency and conflict-of-interest surface.
Technology position. PEM's genuine advantages over alkaline are fast dynamic response (ramps with intermittent renewables), high current density and small footprint — real for grid-coupled green-H2. ITM is one of the few PEM pure-plays at scale (peers: Plug Power, Siemens Energy Silyzer, Cummins/Accelera, Ohmium; Nel does both).
But the moat is thin. (1) No cost moat — alkaline (thyssenkrupp nucera, John Cockerill, LONGi, Chinese OEMs) is structurally cheaper on nickel/iron and dominates GW-scale tenders; Chinese alkaline is a deflationary force. (2) Switching costs are project-level, not franchise-level — each plant is re-tendered. (3) IP is contestable — PEM know-how is diffusing; iridium-reduction is an industry race, not an ITM-only breakthrough. (4) Bargaining power is weak — a sub-£45m-revenue supplier negotiating with Shell/RWE/Uniper has little pricing leverage, which is exactly why the legacy book was loss-making.
Where a real edge could form: (a) CHRONOS + AutoStacker automation if the −40% cost claim survives contact with production — a manufacturing/cost edge is the only durable moat in commoditising hardware; (b) Hydropulse converting ITM from price-taking vendor to offtake-owning producer, which would create recurring revenue and demand-pull it controls; (c) UK-sovereign / NATO positioning (GB Energy stake + Rheinmetall) as a non-Chinese, allied-supply-chain electrolyser champion. All three are promises, not moats, in July 2026.
segments.csv empty → all ``. ITM does not report clean product-segment P&L; the meaningful cuts are revenue line and geography:
Latest reported: H1 FY2026 (six months to 31 Oct 2025), reported 29 Jan 2026:
FY2026 guidance (reiterated Jan 2026, upgraded in the ~May 2026 year-end trading update): revenue £40–43m (from £35–40m; +35% YoY), adjusted EBITDA loss £27–29m (£4m YoY improvement, implying FY2025 adj EBITDA loss ~£31–33m ``), year-end cash £170–175m (pre the Q2-2026 GB Energy raise). The May update said FY revenue would land ahead of guidance with EBITDA loss within range.
Balance sheet. Net cash ~£175–215m depending on the timing of the £40m Great British Energy subscription (Q2 2026); zero debt. This is the opposite of a going-concern story — ITM is cash-rich; the risk is not insolvency but value-destructive cash deployment.
Market reaction / read-through. The tape has treated each print as confirmation of the turnaround; combined with the Rheinmetall LOI, GB Energy stake and MSCI UK Small Cap inclusion, the stock re-rated +~260% over the trailing year. Unusual vs its own history: losses are narrowing on rising revenue and cash is holding — genuinely better than the 2022–23 cash-burn-and-warnings era. The concern is entirely valuation and demand-conversion, not the print itself.
From the H1 FY2026 call (29 Jan 2026):
PEM/electrolyser and adjacent clean-hydrogen names. Market caps `` with dates; multiples not sourced this run are n/a — none are fabricated.
| Company | Ticker | Tech | Mkt cap (USD) | EV/Sales | P/E | Notes |
|---|---|---|---|---|---|---|
| ITM Power | ITM.L | PEM | ~$1.0–1.1bn (£0.78–0.81bn) | ~14x fwd `` | n/a (lossmaking) | Pure-play PEM; ~£190m net cash; guided FY26 rev £40–43m |
| thyssenkrupp nucera | NCH2.DE | Alkaline + chlor-alkali | ~$1.26bn | n/a | n/a | Has real chlor-alkali revenue; GW-scale alkaline leader |
| Nel ASA | NEL.OL | Alkaline + PEM | n/a | n/a | n/a (lossmaking) | First-ever positive gross margin ~+5% |
| Plug Power | PLUG | PEM + fuel cells + H2 | n/a (px ~$2.81, +42% YTD) | n/a | n/a (lossmaking) | Losses narrowing, break-even goal 2026 |
| Ceres Power | CWR.L | SOEC/SOFC (licensor) | ~$0.83bn | n/a | n/a | Royalty/licence model — different economics |
| Bloom Energy | BE | SOFC/SOEC | ~$80–88bn | n/a | n/a | Re-rated as AI-data-centre power — not a clean comp |
Read: ITM at ~£800m/~14x forward sales is richly valued for a sub-£45m-revenue, lossmaking hardware maker, and sits above alkaline leader thyssenkrupp nucera on market cap despite nucera having real revenue and the cheaper, GW-dominant technology. The peer set is uniformly pre-profit or licence-model; there is no clean earnings multiple to anchor to — which is precisely why valuation is contested (see Lens 12).
The name is a volatility machine — a textbook thematic boom-bust-boom ``:
What the market actually reacts to: (1) the hydrogen theme (sector risk-on/off dominates the beta), (2) government money and index flows, (3) marquee partner headlines (Shell, GB Energy, Rheinmetall) — far more than fundamentals. Order conversion and cash discipline have mattered less to the tape than narrative catalysts. That cuts both ways for anyone taking a position.
insider-transactions.csv absent; a CFO on-market purchase was noted.financials.csv empty; no SEC filings (no CIK). Assessment from public results + press ``:
Regulatory findings (required).
Bottom-up from FY2026 guidance (rev £40–43m, adj EBITDA loss £27–29m, net cash ~£175–215m). ITM is lossmaking, so the honest projection is revenue + EBITDA path + net-cash runway, not EPS (EPS stays negative across the window; a P/E is meaningless). All ``, inputs labelled.
| Path | FY2027 rev | FY2028 rev | FY2029 rev | Adj EBITDA breakeven | Net cash at breakeven |
|---|---|---|---|---|---|
| Bear | ~£45m (flat-ish; FIDs slip) | ~£55m | ~£65m | not reached in window | ~£90–120m (steady burn) |
| Base | ~£60m (+~45%) | ~£85m | ~£110m | ~FY2028 if ~200 MW new orders book | ~£120–150m |
| Bull | ~£80m | ~£130m | ~£190m+ (CHRONOS + Hydropulse molecules) | ~FY2027–28 | cushion + Hydropulse capex draw |
Inputs: base assumes reservation-to-order conversion of ~1–2 marquee German projects/yr, standardised-product gross margin turning positive by FY2027, CHRONOS cost-down from 2028, and Hydropulse contributing first molecule revenue FY2028+ . **Runway is not the risk** (~£190m net cash vs ~£25–29m annual EBITDA loss ≈ **6–7 years of runway** even before grants ) — demand conversion is.
Per --watchlist rules and the brief, no
forecast.ts createis logged (breadth mode). The scoreable base-case forecast to log later, on a/thesispass: "ITM.L books ≥200 MW of firm new electrolyser orders (not reservations) by FY2027 year-end" and "ITM.L reaches adjusted-EBITDA breakeven by FY2028" — the two hinges of the whole thesis.
Bull case. A genuinely de-risked turnaround with an option on the entire European green-H2 build-out. Losses halving, 71% profitable backlog, ~£190m net cash and zero debt, a right-sized 1.5 GW factory, a next-gen stack (CHRONOS) targeting −40% cost / −40% iridium, and a demand-creation engine (Hydropulse) that could convert ITM from lumpy vendor to recurring hydrogen producer. Sovereign/allied tailwinds — GB Energy's ~10% strategic stake and the Rheinmetall NATO-PtX LOI — position ITM as the non-Chinese, UK-based electrolyser champion at the exact moment energy security is a policy priority. If even a fraction of the 710 MW Stablegrid / 150 MW RWE / 100 MW REFHYNE II reservations convert to firm orders, revenue compounds off a tiny base and the ~14x sales looks cheap in hindsight. Berenberg's 200p (Buy) reflects this path.
Bear case (2–3 permanent-impairment risks). (1) The demand isn't there. The green-H2 market is in a FID graveyard — the EU Hydrogen Bank's 2nd auction (late 2025) saw 7 projects / 1.88 GW of 2.33 GW winning capacity withdraw despite €1.2bn of grants, and US 45V was gutted by the OBBBA (construction-start cutoff ~2027–28); ~50+ projects publicly cancelled; unsubsidised green H2 is $2.50–7.00/kg and uncompetitive. ITM's reservation pipeline is options on projects that keep dying. (2) No cost moat vs cheap Chinese/alkaline — GW-scale tenders favour alkaline economics; PEM's iridium exposure is a structural cost headwind CHRONOS only partially offsets. (3) Hydropulse turns a cash-rich equipment maker into a capital-intensive project developer competing with its own customers and burning the net-cash cushion. Pre-mortem (18 months out, thesis broken): two flagship German FIDs slip to 2028+, order intake stalls, customer advances unwind into real cash burn, the Rheinmetall LOI never becomes a firm order, the hydrogen theme rolls over, and the stock round-trips toward its ~57p low / net-cash floor (~27p/share) — a ~40–75% drawdown from ~113p with the business itself unharmed.
Are multiples too high? On any fundamental basis, yes — ~14x forward sales for a lossmaking hardware maker above a revenue-generating alkaline leader is a theme/sovereign premium, not an earnings-supported valuation. Contrarian view (what the market refuses to see): the market is treating the Rheinmetall/GB-Energy/CHRONOS narrative as demand proof when it is demand hope — the one metric that would settle the debate, firm-order conversion of the MW reservations, has not yet happened, and the broader industry is providing daily evidence that European hydrogen FIDs are the binding constraint, not electrolyser supply.
Dismantling the bull case. Where the money is concentrated: a handful of German mega-projects (Stablegrid, RWE, REFHYNE II) that are reservations, not orders — if two slip or die, the growth story evaporates. Why the moat is weaker than bulls think: ITM sells a commoditising machine into re-tendered projects with no pricing power against Shell/RWE/Uniper; the cheaper technology (alkaline) wins GW-scale, and China is the deflation engine. Most dangerous competitor bulls underestimate: Chinese alkaline OEMs (LONGi, and the CJH/Cockerill-Jingli axis) on price, plus thyssenkrupp nucera on scale and balance sheet. Worst capital-allocation risk: Hydropulse — funding build-own-operate plants would convert the pristine ~£190m net-cash balance sheet (the actual reason to own the stock through the last bust) into an illiquid, capital-hungry developer book, and puts ITM in competition with its own electrolyser customers. Assumptions that must hold for ~113p: European hydrogen FIDs re-accelerate, reservations convert, CHRONOS hits its −40% cost target on schedule (2028), and the theme premium persists. If growth disappoints 20–30%: at ~14x sales the de-rating is violent — the floor is net cash (~27p/share), and the stock has visited ~57p within the last year. Single permanent-impairment scenario: a second wave of legacy/warranty provisions on POC-recognised contracts (a repeat of 2022) that shatters the "we've fixed execution" narrative — plausibility low-to-moderate, but it is the exact failure mode this company has already lived through once.
Research Trail
Covered in the Knowledge Base
Energy
The most physically elegant fusion bet per dollar — a no-magnet, no-laser Z-pinch ~9x more capital-efficient than the tokamak leaders — but the April-2026 fission pivot is the tell: Zap is now a near-term fission-revenue company wearing a fusion halo. Underwrite the falsifiable milestones (independently-verified Q≥1 at ~650 kA; a signed 4S/fission milestone contract), not the 2030s grid dream. WATCHING · MEDIUM.
The cleanest listed way to own physical uranium at a discount — at ~527p the market prices YCA's U3O8 near ~$70/lb vs ~$85 spot and ~$91.50 term; the discount, not a uranium view, is the edge. It closes if the buyback + a firm spot bid hold; the thesis breaks if uranium rolls over or the ~15% structural discount becomes permanent. This is levered beta to one variable with a fee lid, not an operating business.